Breast cancer
Conditions
Brief summary
Endoxifen levels after three months of continuous use of 20mg (standard dose) of tamoxifen, Tamoxifen resistance defined as Ki67 >10% after three weeks of tamoxifen use according to an adequate dosing schedule, Intratumoral endoxifen levels after three weeks and Ki67 response defined as difference between Ki67 percentage for and Ki67 percentage after three weeks of tamoxifen according to an adequate dosing schedule
Detailed description
Ki67 percentages on tumor material, Levels on estradiol and progesterone in blood after three weeks and three months of tamoxifen treatment, Ki67 percentages on tumor material measured by the pathologist and measured by an AI algorithm, Change in scores of the FACT-ES questionnaire
Interventions
DRUGTAMOXIFEN
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoxifen levels after three months of continuous use of 20mg (standard dose) of tamoxifen, Tamoxifen resistance defined as Ki67 >10% after three weeks of tamoxifen use according to an adequate dosing schedule, Intratumoral endoxifen levels after three weeks and Ki67 response defined as difference between Ki67 percentage for and Ki67 percentage after three weeks of tamoxifen according to an adequate dosing schedule | — |
Secondary
| Measure | Time frame |
|---|---|
| Ki67 percentages on tumor material, Levels on estradiol and progesterone in blood after three weeks and three months of tamoxifen treatment, Ki67 percentages on tumor material measured by the pathologist and measured by an AI algorithm, Change in scores of the FACT-ES questionnaire | — |
Countries
Netherlands
Outcome results
None listed